Intended Use
For In Vitro Diagnostic Use
Summary and Explanation
Apolipoprotein E4 (APOE4) is a protein known to contribute to the onset of Alzheimer’s disease. While it is expressed in many organs, in the brain APOE4 has been associated with deposition of insoluble amyloid plaques Aβ40 and Aβ42 in the interstitial fluid in the cortex and hippocampus. APOE isoforms are produced by astrocyte cells, and assist in the delivery of lipids such as cholesterol to the neurons. LDL receptor-related protein 1 (LRP1) metabolizes APOE and Aβ plaques; in knockout mice models, the presence of APOE4 (more than other isoforms) was shown to increase the deposition of insoluble Aβ40 and Aβ42 in the presence of LRP1.
APOE4 has been found to be a genetic factor in the pathology of Alzheimer’s disease, Lewy Body Dementia, and Parkinson’s Disease. The mechanisms of overproduction of plaques and interference in clearing the amyloid peptides result in the accumulation of Aβ42. The Aβ plaque burden in the brains of Alzheimer’s patients with APOE4 isoform is around 2.7 times that of patients with APOE3 isoform, indicating a role of APOE4 in Aβ metabolism. The accumulated Aβ oligomers have been shown to disrupt synaptic function- the loss of dendritic spines contributes to the loss of cognitive function. APOE4 has also been shown to predict better prognosis than APOE2 isotype in melanoma patients, but overall APOE serum levels predict immunosuppression and worse patient survival in Pancreatic Ductal Cell Carcinoma.
Synonyms: APOE, apoe4, anti-apoe4, anti apoe4, apolipoprotein E, anti-apoE, anti apoE
